Teva's new roy­al­ty deal; Se­lec­ta merges with Carte­sian; Vir's he­pati­tis da­ta

Te­va inks deal with Roy­al­ty Phar­ma for schiz­o­phre­nia drug: The Is­raeli drug­mak­er said Mon­day that it will re­ceive $100 mil­lion to com­plete an on­go­ing Phase III tri­al for a long-act­ing in­jectable form of olan­za­p­ine. That study is ex­pect­ed to read out in the sec­ond half of 2024. The part­ners have the op­tion to in­crease that amount to $125 mil­lion, and Te­va has agreed to pay Roy­al­ty back with­in five years of FDA ap­proval plus “low- to mid-sin­gle dig­it roy­al­ties.” If Te­va doesn’t file for FDA ap­proval fol­low­ing the Phase III read­out, it will pay Roy­al­ty back 125% of the amount it was giv­en. Olan­za­p­ine is bet­ter known as Zyprexa, which has been mar­ket­ed by Eli Lil­ly for psy­chot­ic dis­or­ders since the 1990s. “It’s val­i­da­tion and an op­por­tu­ni­ty for us to keep dri­ving the growth, as well as be­ing thought­ful about how we’ve man­aged our op­er­at­ing ex­pen­di­tures go­ing for­ward,” Te­va CEO Richard Fran­cis told End­points News. — Nicole De­Feud­is

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER